Seattle Genetics
NAS:SGEN
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
About

BiotechnologyFounded 1997
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Headquarters
Executives
Name | Title | Gender |
Jean I. Liu | Executive VP-Legal Affairs & General Counsel | Female |
Vaughn B. Himes, PhD | Chief Technology Officer | Male |
Perry Fell, PhD, MBA | Founder | Male |
Clay B. Siegall, PhD | Chairman, President & Chief Executive Officer | Male |
Eric L. Dobmeier | Chief Operating Officer | Male |
Todd E. Simpson, CPA | Chief Financial Officer | Male |
Jonathan Drachman, MD | Chief Medical Officer, EVP-Research & Development | Male |
Christopher Pawlowicz | Executive Vice President-Human Resources | Male |
Elaine Waller, PhD | Executive Vice President-Regulatory Affairs | Female |
Peggy Pinkston | Executive Director-Investor Relations | Female |
Mindful Investing Summary
Seattle Genetics - Competitors and Related Companies
How Seattle Genetics stacks up to its peers in theBiotechnology industry or with competing business segments.
Seattle Genetics
NAS:SGEN
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
Spectrum Pharmaceuticals
NAS:SPPI
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
ImmunoGen
NAS:IMGN
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Biogen
NAS:BIIB
Biotechnology
—
MEGA cap
(—)
—
since start of 2022
—
GlaxoSmithKline
LON:GSK-GB
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Pfizer
NYS:PFE
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—